ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death

Guo, Fang; Yang, Zhi; Sehouli, Jalid; Kaufmann, Andreas M.*南方医科大学; 1
Current Oncology2022-4DOI: 10.3390/curroncol29040229
9被引3阅读
引用收藏
分享

摘要

Epithelial ovarian cancer (EOC) is the leading cause of gynecological cancer-related death. The high mortality and morbidity associated with EOC are mostly due to late diagnosis and chemotherapy drug resistance. Currently, the standard first-line chemotherapy regimen is systemic administration of platinum-based chemotherapy combined with a taxane. A major problem besides cisplatin resistance (occurring in nearly one-third of patients) is the greater toxicity of the drug combinations. A synergistic treatment with drug supporting activity could maximize the cytotoxic effects of chemotherapeutic agents on tumor cells while decreasing the dosage of each drug to potentially reduce toxicity. The ALDH-blocking agent Disulfiram (DSF), a clinically approved drug used for alcoholism treatment, has displayed promising anti-cancer activity. We previously described that blocking ALDH activity enhances the induction of apoptosis, especially in ovarian cancer stem cells treated with chemotherapeutic agents. In this study, we further investigated the synergistic effect of DSF in combination with cytotoxic chemotherapeutic drugs. The concentration of each chemotherapeutic agent could be significantly reduced with sustained efficacy on tumor cell apoptosis in cell lines in vitro (Dose-Reduction Index at IC50 from 1 to 50). Moreover, the potential chemo-sensitizing effects of DSF on ALDH-associated cisplatin-resistant ovarian cancer stem cells were also investigated and shown that in contrast to its high resistance to cisplatin, the cisplatin-resistant cells remain very sensitive to DSF-induced cytotoxicity (apoptosis and necrosis: cisplatin-resistant cells vs. parental cells: 60.4% vs. 20.5%). In combination with DSF and cisplatin, relatively more apoptosis and necrosis were induced in cisplatin-resistant cells than in their parental cells (apoptosis and necrosis: cisplatin-resistant cells vs. parental cells: 81.5% vs. 50.1%). A transcriptome analysis identified that ALDH was mainly enriched in the cancer-associated fibroblasts and showed that ALDH plays roles in responding to oxidative stress, metabolisms, and energy transition in the ALDH-associated cisplatin-resistant ovarian cancer stem cells. In conclusion, our data demonstrate a key role of ALDH-associated cisplatin-resistant cancer stem cells and identifies DSF as a potential adjuvant for a rational protocol design by computational quantitative assessment in vitro on ovarian cancer cell lines. Our work contributes to resolving the ALDH-associated cisplatin resistance and provides a resource for the development of novel chemotherapeutic regimens.

学科与关键词

关键词
chemotherapy resistanceregimensapoptosistumor therapyadjuvant therapy
相关
加载中…
  • Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
    Tang, Bin; Wu, Min; Zhang, Lin; Jian, Shuyi; Lv, Shiyi; Lin, Tongyuan; Zhu, Shuangshuang; Liu, Layang; Wang, Yixue; Yi, Zhengfang*; Jiang, Feiyun*Frontiers in Oncology, 2023, 13: 1154073.被引 2
  • Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy
    Huddle, Brandt C.; Grimley, Edward; Chtcherbinine, Mikhail; Buchman, Cameron D.; Takahashi, Cyrus; Debnath, Bikash; McGonigal, Stacy C.; Mao, Shuai; Li, Siwei; Felton, Jeremy; Pan, Shu; Wen, Bo; Sun, Duxin; Neamati, Nouri; Buckanovich, Ronald J.; Hurley, Thomas D.; Larsen, Scott D.*European Journal of Medicinal Chemistry, 2021, 211: 113060.被引 10
  • TAZ Regulates the Cisplatin Resistance of Epithelial Ovarian Cancer Cells via the ANGPTL4/SOX2 Axis
    Li, Caihong*; Wang, Qin; Luo, Youzhen; Xiang, JuanAnalytical Cellular Pathology-Cellular Oncology, 2022, 2022: 5632164.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Current Oncology
发表日期
2022-04
卷期
第 29 卷, 第 4 期
页码
2808-2822
DOI
10.3390/curroncol29040229
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82002745]; Basic Research Program Funding of Shenzhen, China [JCYJ20190809184203668]; Basic Research and Research for Application Funding of Guangdong Province, China [2019A1515110011]

作者

  • G

    Guo, Fang (第一作者)

    southern med univ

  • Y

    Yang, Zhi

    southern med univ

查看全部 4 位作者收起作者
  • S

    Sehouli, Jalid

    1

  • K

    Kaufmann, Andreas M. (通讯)

    1

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417